Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vcMMAE
- Development stage
- Preclinical
- Lead developer
- Skagen
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
vcMMAE is a linker-payload system commonly utilized in antibody-drug conjugates (ADCs). It comprises a valine-citrulline (vc) dipeptide linker conjugated to monomethyl auristatin E (MMAE), a potent synthetic antimitotic agent. MMAE exerts its cytotoxic effects by disrupting microtubule polymerization, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells. When incorporated into an ADC, the vc linker is designed to be cleaved by lysosomal proteases within the tumor cell, thereby releasing the active MMAE payload specifically at the target site.
- Other names
- valine-citrulline monomethyl auristatin E
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vcMMAE.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vcMMAE.